HomeKYTX • NASDAQ
add
Kyverna Therapeutics Inc
Previous close
$11.07
Year range
$6.75 - $35.06
Market cap
477.29M USD
Avg Volume
878.62K
P/E ratio
-
Dividend yield
-
Primary exchange
NASDAQ
In the news
Financials
Income Statement
Revenue
Net income
(USD) | Mar 2024info | Y/Y change |
---|---|---|
Revenue | — | — |
Operating expense | 5.78M | 111.49% |
Net income | -26.69M | -139.55% |
Net profit margin | — | — |
Earnings per share | -1.12 | — |
EBITDA | -28.01M | -149.31% |
Effective tax rate | — | — |
Balance Sheet
Total assets
Total liabilities
(USD) | Mar 2024info | Y/Y change |
---|---|---|
Cash and short-term investments | 369.79M | 620.54% |
Total assets | 389.98M | — |
Total liabilities | 28.99M | — |
Total equity | 360.99M | — |
Shares outstanding | 43.12M | — |
Price to book | 1.32 | — |
Return on assets | -30.37% | — |
Return on capital | -32.85% | — |
Cash Flow
Net change in cash
(USD) | Mar 2024info | Y/Y change |
---|---|---|
Net income | -26.69M | -139.55% |
Cash from operations | -25.52M | -122.77% |
Cash from investing | -122.88M | -999.88% |
Cash from financing | 338.05M | 234,856.25% |
Net change in cash | 189.64M | 9,137.46% |
Free cash flow | -16.84M | — |
About
Founded
2018
Headquarters
Website
Employees
100